Skip to main content Accessibility help
×
Home

Adinazolam sustained release formulation in the treatment of panic disorder: a pilot study

  • David V. Sheehan (a1), Ashok B Raj (a2), K. Harnett-Sheehan (a3), Sonia Soto (a4) and Carl P. Lewis (a5)...

Abstract

This is the first report on the use of the sustained release formulation of adinazolam in the treatment of panic disorder. A six week open lable trial followed by a 1-6 week taper/discontinuation phase was used to assess the safety and efficacy of adinazolam (Deracyn-SR) in the treatment of 10 outpatients with panic disorder and agoraphobia. Adinazolam-SR was well tolerated and produced a rapid improvement in panic and limited symptom attacks, anxiety, phobias, disability, and depressive symptoms. Mean ±S.D. duration of therapeutic action of each dose of this formulation was 12.2±2.3 hours. This is longer than the duration of therapeutic action of other benzodiazepine formulations studied to date for the treatment of panic disorder. Frequency of relapse, rebound and withdrawal symptoms was similar to that found on taper/discontinuation from alprazolam.

Copyright

References

Hide All
1.Greenblatt, DJ, Shader, RI, Abernathy, DR. Current status of benzodiazepines (first of 2 parts), New Engl J Med 1983; 6: 354358.
2.Herman, J. Interview in Currents in Affective Illness 1988; 7(2): 510.
3.Sheehan, DV, Coleman, JH, Greenblatt, DJ, et al.Some biological correlates of panic attacks with agoraphobia and their response to a new treatment. J Clin Psychopharmacology 1984; 4(2): 6675.
4.Pyke, RE, Cohn, JB, Feighner, JD, Smith, WT. Open label studies of adinazolam in severe depression. Psychopharmacol Bull 1986; 19: 9698.
5.Feighner, JP. Controlled studies of Deracyn (adinzaolam mesylate) for major depressive episode. Abstract presented at NCDEU Annual Meeting, Key Biscayne, Florida, 1985.
6.Lahti, RA, Sethy, VH, Barsuhn, C, Hester, JB. Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology 1983; 22: 1277–82.
7.Amsterdam, J, Kaplan, M, Potter, L, Bloom, L, Rickels, K. Adinazolam, a new triazolobenzodiazepine and imipramine in the treatment of major depressive disorder. Springer Verlag, 1986.
8.Dunner, D, Myers, J, Khan, A, Avery, D, Pyke, R. Adinazolam, a new antidepressant: findings of a placebo-controlled double-blind study in outpatients with major depression. J. Clin Psychopharmacol 1987; 7: 170172.
9.Pyke, RE, Greenberg, HS. Double blind comparison of alprazolam and adinazolam for panic and phobic disorders. J Clin Psychopharmacol 1989; 9(1): 1521.
10.Fleishaker, JC, Phillips, JP, Lau, HSH. Effect of food on the bioavailability of adinazolam from a sustained release formulation: effect of meal timing and lack of dose dumping. Biopharm Drug Disposit. 1990 (in press).
11.American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 3rd edition revised (DSM-1II-R). Washington, D.C. 1987.
12.Spitzer, RL, Williams, JBW. Structured clinical interview for DSM-III-R. Biometrics Research Dept., New York State Psychiatric Institute, New York, 1987. Upjohn Version (SCID-UP-R).
13.Sheehan, DV. The Anxiety Disease. New York, Bantam Books (revised paperback edition), 1986.
14.Hamilton, M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50.
15.Hamilton, M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychology 1967; 6: 278296.
16.Derogatis, LR, Lipman, RS, Rickles, K, Uhlenhuth, EH, Covi, L. The Hopkins Symptom Checklist (HSCL): A self report symptom inventory. Behav Sci 1974; 19 (1): 115.
17.Beck, AT, Ward, CH, Mendelson, M, Mock, JE, Erbaugh, JK. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561571.
18.Winer, BJ. Statistical principles in experimental design. New York: McGraw Hill, 1971.
19.Pecknold, JC, Swinson, RP, Kuch, K, Lewis, CP. Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial, III Discontinuation effects. Arch Gen Psychiatry 1988; 45: 429436.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed